In a landmark decision aimed at ensuring equitable procurement policies in the field of Medical Technology (MedTech), the Department of Pharmaceuticals (DoP) has issued a Global Tender Enquiry (GTE) exemption list, thereby addressing crucial concerns raised by global and local medical device manufacturers. This development, announced on June 28, 2024, marks a significant step towards enhancing transparency and fairness in procurement practices of medical devices in the country.

In a notification issued Under Rule 161 (iv) of the General Financial Rules (GFRs) 2017, the DoP has granted a general exemption based on requests from the Ministry of Health and Family Welfare (MoH&FW).

This exemption will remain effective until 31st March 2027, or until further orders, from the instructions previously issued by the Department in its Office Memorandums dated 15th May 2020 and 28th May 2020, the notification read.

Hailing the move as a "pathbreaking effort" towards fair policy-making, Mr. Pavan Choudary, Chairman of the Medical Technology Association of India (MTaI) emphasized that this initiative would ensure a level playing field, enbling continued access to quality medical products for patients while promoting India as a reliable manufacturing hub.

Mr. Choudary highlighted the significance of this decision in bolstering India's reputation as a trustworthy destination for medical device manufacturing and its positive impact on exports and foreign investments.

The decision follows a rigorous review process conducted over two days by a committee chaired by the Secretary of the Department of Pharmaceuticals. The committee included representatives from the DoP, Central Drugs Standard Control Organization (CDSCO), Directorate General of Health Services (DGHS), and All India Institute of Medical Sciences (AIIMS). More than 100 representatives from global and domestic MedTech companies participated in the review process, presenting detailed justifications and supporting documents to substantiate their claims.

Mr. Choudary acknowledged that while some claims were not upheld during the review, the process was fair and impartial, guided by inputs from medical experts and industry stakeholders. He praised the government's commitment to ensuring justice for both patients and the industry, noting that such thorough policy-making efforts were unprecedented and commendable.

This decision by the Department of Pharmaceuticals is expected to have far-reaching implications, ensuring that procurement practices align with global standards while supporting domestic manufacturing capabilities. It underscores the government's proactive approach towards fostering a robust and equitable healthcare ecosystem in India.